Eli Lily, Summit Therapeutics and Vertex Pharmaceuticals have important current clinical trials.
The shares of these drug manufacturers can jump if the studies are positive.
All three companies have attractive prospects beyond that.
10 shares we like better than Eli Lily ›
Few things can discard the pharmaceutical company shares as a positive results from long -awaited clinical trials. However, long -term investors must have a balanced approach to potentially positive data indications. Putting aside the fact that it is impossible to predict the result of a clinical trial in advance, even when the results are in accordance with Wall Street standards, it is hardly worth investing in the company, unless there are any other good reasons to think that you will perform a lot of long periods.
That is why you may want to look more closely Eli Lily(Nyse: lly)., Summit Therapeutics(Nasdaq: SMMT)and Vertex Pharmaceuticals(Nasdaq: VRTX)S All three drug manufacturers must relend the results of key clinical trials within the next 18 months, and all three have strong prospects for the next five years.
Image source: Getty Images.
In April, Eli Lily reported positive Phase 3 results for her oral candidate for GLP-1, orforglipron. While the market responds positively to this development, the study in question focuses on patients with diabetes and uses the A1C reduction as a major endpoint. All glances will be directed to current later -stage studies for Orforglipron in obesity; He must release data from at least one of these clinical trials within next year.
Eli Lily’s work in weight management has been central to the last few years. The pharmaceutical leader can again make a breakthrough, being one of the first to release a highly effective oral drug GLP-1 against obesity. As the current options apply subcutaneously, you can expect Orforglipron to reach a reasonable level of success in the market – but this is only if it performs well in phase 3 for obesity. If he doesn’t, Lily’s shares can immerse themselves.
However, the shares still have to be a purchase. It is true that Orforglipron would strengthen Lily’s healthy composition. But even if it does not reach its expectations in late -stage surveys, the company has several other candidates in development, including retatutid, which is also in phase 3 tests.
In the meantime, Lily continues to generate consistent financial results. Revenues and profits are growing with a good clip and this should continue in the foreseeable future.
Finally, Eli Lily is an excellent stock of dividend growth. Although the results of Phase 3 Orforglipron tests in obesity will be important for monitoring, the stock should be performed quite in the long run, regardless of the result of these tests.
Summit Therapeutics develops Ivonescimab, a cancer medicine of which licensing AcesoBiopharma based in China. Ivonessimab has already been approved in China; However, Summit must conduct clinical trials elsewhere to support approval in the US, Europe and other regions where it has marketing rights.
At least one of these studies will be of particular interest to investors. Summit tests its crown jewel in a late -stage test against MercateKeytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study continues and has a great chance to see data from the best lines from it by the end of next year.
Summit shares increased when it reported that Ivonescimab had coped better than Keytruda to reduce the risk of relapse or death in patients with NSCLC in a study conducted in China. However, reproduction of this result can again tear off the price of the shares. On the reverse side, the price of Summit shares will move in the wrong direction if the results are not what Wall Street expects.
Do you have to buy stock? For me, the prospects of Summit Therapeutics for the next five years seem attractive. Ivonescimab is tested in a number of different cancers and looks very promising in NSCLC, which can be its most important market.
Even with the ability not to perform so well in studies outside China, it has already been approved by regulatory authorities in one region, reduces the risk of significant clinical and regulatory failures. Ivonessimab looks like a potential pipeline in medicine. And if you are investing in Summit Therapeutics now, you can reap the benefits of your leading candidate’s potential.
Vertex Pharmaceuticals is a proven innovator. The company’s strategy is to develop drilling medicines where there is a great unmet need. One of the new goals of Vertex is type 1 diabetes (T1D). There are no treatments for this chronic illness, but biotechnics candidate Zizhezel can be a functional cure, in the sense that it can restore patients’ ability to produce their own insulin – something that people with T1D cannot do.
In the phase of 1/2 part of the current clinical trial phase 1/2/3, 10 out of 12 patients who received Zimislecel were insulin -free after one -year follow -up. All 12 were without severe hypoglycemic events after 90 days.
Vertex must have data from the late stage of this current clinical trial within next year. The positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a pleasant addition to the Vertex portfolio.
Biotechnology remains a leader in the drug market that treats the main genetic causes of cystic fibrosis, a business that still helps it to achieve strong revenue and growth of profit. In addition, Vertex has added several medicines to his portfolio over the last five years, including Journavx for acute pain and a case for two rare blood disorders.
Vertex Pharmaceuticals PipeLine also has promising programs beyond Zimislecel. In addition to announcing the results of the clinical examination for this promising T1D therapy, the stock will be in an excellent position for implementation.
Before you buy shares in Eli Lily, think about it:
Thehe Motley Fool stock adviser Analyst team has just identified what they think is 10 best shares For investors to buy now … And Eli Lily was not one of them. The 10 shares that made the abbreviation could lead to the return on monsters in the coming years.
Consider when Netflix Make this list on December 17, 2004 … If you have invested $ 1,000 at the time of our recommendation, You will have $ 652,133!* Or when Nvidia Make this list on April 15, 2005 … If you have invested $ 1,000 at the time of our recommendation, You will have $ 1.056 790! **
It is now worth noting Stock adviser The total average return is 1048%-Market on market market compared to 180% for the S&P 500. Don’t miss the latest top 10 list available when you join Stock adviserS
See the 10 shares »
*Stock Advisor since July 21, 2025
Proser Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. Motley Fool has positions and recommends Merck, Summit Therapeutics and Vertex Pharmaceuticals. Motley Fool has a policy of disclosure.
3 Health stocks for purchase before announcing that the results of clinical trials for change of game were initially published by Motley Fool
